We utilized the closed window technique to study the in vivo responses of rat pial arterioles to super fused adenosine agonists. Adenosine and its analogs di lated pial arterioles and exhibited the following order of potency: 5' N-ethylcarboxamide adenosine (NECA) > 2-chloroadenosine (2-CADO) > adenosine = R-W'-phenyl isopropyladenosine (R-PIA) = S-PIA > N6-cyclo hexyladenosine (CRA). This potency profile suggests
that cerebral vasodilation is mediated through the A2 re ceptor. F orskolin (10 -9 M) potentiated the vasodilation caused by 10-6 M NECA, thus implicating adenylate cy clase activation during NECA-induced vasodilation and providing further support for involvement of the A2 re ceptor. Key Words: Adenosine receptor-Cerebral blood flow-Cranial window-Cyclic AMP.
cyclic AMP production. In addition, R-PIA is more effective than S-PIA at the AI receptor, whereas there is little stereospecificity of the PIA isomers at the A2 receptor.
Adenosine analogs have been utilized in vitro to characterize adenosine receptors in cerebral vessels by means of radioligand binding (Palmer and Ghai, 1982; Kalaria and Harik, 1986) , adenylate cyclase assay (Schutz et aI., 1982; Edvinsson and Fred holm, 1983) , and rank orders of potency in relaxing isolated cerebral vessels (Edvinsson and Fredholm, 1983; McBean et aI., 1988) . The consensus is that adenosine-induced vasodilation is mediated through the Az receptor. However, the in vivo effect of these analogs on cerebral vessels is not known. The purpose of the present study is to examine, in vivo, the responses of pial arterioles to adenosine and some of its analogs.
In addition, we studied the vasodilative action of forskolin and its effect on the potent adenosine an alog, NECA. Forskolin directly activates adenylate cyclase through a mechanism independent of either receptor mediation or GTP binding protein (G pro tein) activation (Seamon and Daly, 198 1) . At low concentrations, forskolin is known to potentiate the effect of receptor-mediated stimulation of adenylate cyclase (Daly et aI., 1982) . If the effects of NECA are mediated through the Az receptor (which stim-ulates adenylate cyclase), then forskolin may poten tiate NECA-induced vasodilation.
MATERIALS AND METHODS
Adult male Sprague-Dawley rats weighing 350-400 g were initially anesthetized with 1.5% halothane. The right femoral artery and vein were cannulated for recording MABP and intravenous drug administration, respec tively. The rats were tracheostomized, immobilized with tubocurarine chloride (1 mg/kg, i.v.), and mechanically ventilated. The concentration of halothane was decreased to 0.5-1% and adjusted such that the heart rate and blood pressure of the animals remained stable during surgical manipulation. Oxygen was added to the breathing mix ture, and end-tidal CO2 was continuously monitored and maintained between 3.5 and 4.5%. Periodically, a small amount (0.2 ml) of arterial blood was anaerobically sam pled for measurements of pH, Paco2, and Pao2. Body temperature was maintained at 37° by a heating mat.
The animal's cranium was fixed in a stereotaxic frame and a closed cranial window was prepared to expose the right parietal cortex, as described by Morii et al. (1986) . The window contained three ports: an inflow port for superfusion, an outflow port for drainage of artificial CSF, and a third port for measurement of intracranial pressure. Before superfusion, artificial CSF, made fresh daily, was equilibrated at 37°C with a gas mixture con sisting of 10% O2, 6% CO2, and balance No to maintain the CSF pH within 7.35-7.37. The fluid level of the out flow tube was adjusted to achieve an intracranial pressure of 5 mm Hg.
Solutions in concentrations of 10 -9, 10 -8, 10 -7, 10 -6, 10-5 , and 10-4 M of the following compounds were pre pared in artificial CSF: adenosine (ADO), NECA, 2-chloroadenosine (2-CADO), R-and S-PIA, and N> cy clohexyladenosine (CHA). The adenosine analogs were all obtained from Boehringer Mannheim and aden osine was purchased from Sigma. PIA was first dissolved in 0.5% dimethyl sulfoxide (DMSO) to achieve a 10-4 M solution and then diluted in CSF. This concentration (0.5%) of DMSO was determined not to affect vessel di ameter.
Initially, the resting diameter was measured after su perfusion of artificial CSF. Solutions of each adenosine analog were subsequently superfused in order of increas ing concentration by means of a roller pump for 10 min at 0.25 mUmin. Before changing to a different solution, su perfusion was stopped for the measurement of vessel di ameter. Only one vessel was chosen for dose-response studies in each animal.
In each experiment, up to three agonists were applied in a random order. After determination of the response to the highest agonist concentration (10-4 M), artificial CSF was superfused for 10 min at 0.25 ml/min to wash out agonist solutions and to restore vessel diameter to base line (i.e., vessel diameter before each series of agonist application). The experiment was discontinued if vessel diameter did not return to ±5% baseline within 10 min after agonist washout.
Modified forskolin, 7 -deacetyl-7 -( 4-methylpiperazine) butyrylforskolin (Calbiochem), was dissolved in artificial CSF. In a few preliminary experiments, forskolin solu tions in concentrations of 10 -II to 10 -5 M were applied under the cranial window sequentially to establish the Mean values and standard deviation (SD) were calcu lated for all data. The log of agonist concentration causing 50% arteriolar dilation is expressed as log(EC 5 0). These values were determined by fitting a linear regression line to the steep portions of each individual log concentration response curve according to Tallarida and Murray (1981) . Statistical differences among log(EC 5 0) values were tested using analysis of variance (ANOV A) and the Bon ferroni method of multiple simultaneous comparisons (Wallenstein et al., 1980) . Differences were considered to be significant at the p < 0.05 level. Student's paired t test was employed for the forskolin/NECA data also at the 5% confidence level.
RESULTS
Pial arterioles ranging in diameter from 29.0 to 53.0 !-Lm were studied. As illustrated in Forskolin relaxed pial arterioles 4.88 ± 0.07, n = 6) in a dose-dependent manner.
No significant vasodilation was observed up to a concentration of 10 -9 M, and this concentration of forskolin was then superfused with 10 -6 M NECA to test the involvement of cyclic AMP in NECA induced vasodilation. As shown in Fig. 2 , forskolin potentiated the vasodilation caused by NECA from 58.3 ± 5.5 to 93.0 ± 14.4% (n = 9).
MABP, intracranial pressure, and arterial blood gas parameters were constant throughout the exper imental period. No difference was noted in these parameters among all groups of animals ( Table 2 ).
DISCUSSION
The vasodilative effects of adenosine in a variety of vascular beds, including cerebral (Edvinsson and Fredholm, 1983; McBean et al. , 1988) , coronary (Collis and Brown, 1983; Oei et al. , 1988) , and pul monary (McCormack et al., 1989) , have been attrib uted to the A2 receptor. In a study on isolated cat cerebral arteries precontracted with prostaglandin These results were considered to be consistent with agonist action on the A2 receptor (e .g., Ribeiro and Sebastiao, 1986). Schutz et al. (1982) demonstrated that adenosine agonists stimulated cyclic AMP pro duction in accordance with an A2 type potency pro file. Kalaria and Harik (1986) found A2 but few or no A) receptors in rat and pig cerebral microves sels, as evidenced by the lack of binding of 3 H_ labeled A)-selective agonists (CHA and R-PIA).
The present study is the first to examine the ef fects of adenosine agonists on cerebral arterioles in vivo. We determined that this agonist potency rank order was as follows: NECA > 2-CADO > ADO = R-PIA = S-PIA > CHA. This order indicates A2 Values are mean ± SD. n = number of pial arterioles studied. MABP = mean arterial blood pressure, ICP = intracranial pressure.
Other abbreviations as in Table 1 . ity between adenosine and PIA in our findings, as compared to in vitro studies that generally showed adenosine to be more potent than the PIA isomers at the A2 receptor (Burnstock and Buckley, 1985) .
Since adenosine is rapidly transported into cells and metabolized (Wu and Phillis, 1984; Geiger et aI., 1988) , its concentration at the vascular level may be significantly less than in the perfusate. On the other hand, the adenosine analogs (e.g., 2-CADO) used in this study are resistant to metabolizing enzymes, such as adenosine deaminase (Daly, 1982; Collis and Saville, 1984) .
The actions of the adenosine analogs may also be affected by uptake processes. Adenosine analogs have been shown to compete with adenosine for the cellular transport site (Clanachan et aI., 1987; Gei ger et aI., 1988) . By inhibiting adenosine uptake, the adenosine analogs may increase interstitial adeno sine availability to contribute to their vasoactivity.
Other factors, such as the high lipid solubility of R-PIA (see Burnstock and Buckley, 1985) , should also be considered.
Nevertheless, the agonist potency rank order ob tained in this study is consistent with the hypothesis that pial vasodilation is mediated by A2 receptors. This is further supported by our data on the effect of forskolin on NECA-induced vasodilation. At low concentrations, forskolin is known specifically to augment receptor-mediated activation of adenylate cyclase (Seaman and Daly, 198 1; Daly et aI., 1982) .
Our observation that a nonvasoactive low concen tration (10-9 M) of forskolin potentiated the vasodi lating effect of NECA implicated adenylate cyclase activation, which is a characteristic of the A2 recep tor. These data, however, do not indicate that A2
receptor-mediated vasodilation is caused solely by increased cAMP, since the parallel involvement of other processes, such as calcium influx blockade (Schrader et aI., 1975) , cannot be excluded.
In summary, our results indicate that adenosine analogs dilate pial arterioles in vivo by interacting with the A2 receptor. Moreover, this vasodilating effect is associated with adenylate cyclase activa tion.
